Slide 1: Dimerix Investor Webinar and Presentation
For Immediate Release DIMERIX INVESTOR WEBINAR AND PRESENTATION MELBOURNE, Australia, 05 October 2023: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company invites shareholders to attend its investor webinar to be held Thursday 5th October 2023 at 11am (AEDT), following its licensi
Slide 2: About Dimerix
About Dimerix Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. Dimerix is currently focussed on developing its proprietary Phase 3 product candidate DMX-200 (QYTOVRA®
Slide 3: Investor Update October 2023
ACTIONS FSGS CLINICAL STUDY y al use onl For person @ Dimerix (ASX:DXB) Investor Update October 2023 Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs Authorised for lodgement by the Board of the Company
Slide 4: Forward looking statements
Forward looking statements For personal use only This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be ma
Slide 5: ADVANZ - Leadership in rare disease medicines
ADVANZ - Leadership in rare disease medicines PHARMA >ADVANZ PHARMA makes the ideal commercial partner for Dimerix Cc je) qaADVANZ PHARMA is a global pharmaceutical company and a partner of choice for the commercialisation of Uspecialty, hospital, and rare disease medicines in Europe, Canada, and Au
Slide 6: ADVANZ - a strategic partnership
@ Dimerix/ ADVA\NZ - a strategic partnership PHARMA 2 c je) A Mery Vi Onal For “We are committed to bring innovative rare disease medicines to market which serve a high unmet patient need” “We are excited to announce this partnership with Dimerix, which is aligned with our strategy to be a partner o
Slide 7: Key elements of ADVANZ partnership
Key elements of ADVANZ partnership PHARMA ADVANZ PHARMA acquires exclusive license to commercialise DMX-200 in European Economic Area, Switzerland, UK, Australia, New Zealand and Canada | use only Dimerix to receive up to “AU$230* million in upfront and milestone payments, plus royalties © €6.5 mill
Slide 8: A new era for Dimerix
A new era for Dimerix ¢ Embarking on a new phase of commercial growth following many years of hard work developing and advancing DMX-200 in kidney disease + Partnering discussion ongoing in other territories + Licensing deal marks the first of potentially several agreements globally Dimerix ¢
Slide 9: Global partnering availability
Global partnering availability For personal use only i] Licensed territories (European Economic Area, Switzerland, UK, Canada, Australia, New Zealand) —- DMX-200 Available for licensing - e? QYTOVRA @ Dimerix
Slide 10: Forecast FSGS market size
Forecast FSGS market size > FSGS 7MM market > Current market specifically for FSGS does not exist Cc size estimated to be o U S 3 b 1 DMX-200 is the only drug candidate specifically in oA p.a > Phase 3 development for primary FSGS =) oC Forecast FSGS Market Size S $US p.a m (2032) pad US 85,342! US$
Slide 11: ACTION3 Phase 3 clinical trial
O ACTI IN3 Phase 3 clinical trial FSGS CLINICAL STUDY randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB Part 1: Part 2: Part 3: 72 patients @ 35 weeks treatment 144 patients @ 35 weeks treatment 286 patients @ 104 wee
Slide 12: ACTION3 Part 1 analysis set for March 2024
O ACTICIN3 Part 1 analysis set for March 2024 FSGS CLINICAL STUDY > * Announcement of Part 1 analysis of Phase 3 trial expected on, or around, 15 March 2024* proteinuria vs placebo and the trial is continuing to Part 2 Independent Data Safety Dimerix remains Monitoring Board blinded to raw Based on
Slide 13: Late stage, phase 3 clinical development asset
Late stage, phase 3 clinical development asset > Orphan Drug status providing —= Near term Phase 3 analysis protection through data exclusivity? = outcome announced (“15Mar24') for min 7-10 years, in addition to je) comprehensive patent/IP strategy oO 12) =) = . . Estimated >3b global market © Conti
Slide 14: For personal use only
For personal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN ESG Statement SCAN ME Dimerix HQ 42